The goal of this single arm ,non-interventional, prospective, descriptive study is to evaluate the efficacy of guselkumab treatment in preventing endoscopic recurrence of Crohn's Disease in adult participants who have a documented diagnosis of moderate to severe CD and have undergone an ileocolonic surgical resection. The primary endpoint is Endoscopic recurrence rate at week24.
Patients≥ 18，
Have a documented diagnosis of moderate to severe CD
Have undergone an ileocolonic surgical resection
Has complications of CD, such as short bowel syndrome Currently has or is suspected to have an abscess
Active infection
Currently has a malignancy or has a history of malignancy within 5 years
Shanghai 10th People's Hospital
Lead sponsor
Xian-Janssen Pharmaceutical Ltd.
Collaborator